nfcol.net Neurofibromatosis Clinical Reference · EN / ES
NF1 Criteria NF2 & SWN MEK Therapy Checkup Schedule Archive
EN · Español
Clinical Handbook › About & Archive Heritage

About nfcol.net: Archive Continuity and Editorial Methodology

Transparent archival disclosure honoring the original 2010–2019 Bogota Spanish educational resource cited by the US National Institutes of Health (NIH GARD), alongside our 2026 evidence review standards.

Zero Pharmaceutical Sponsorship · Bilingual EN/ES Open Clinical Reference
Clinical researcher reviewing bound medical reference volumes and printed consensus guidelines in an academic medical library

1. Historical Origin & Transparent Non-Affiliation Statement

Archival Transparency Disclosure: Between 2010 and 2019, nfcol.net operated in Bogota, Colombia as Todo Sobre Neurofibromatosis (NEUROCOL), an educational resource cited by the US National Institutes of Health Genetic and Rare Diseases Information Center (NIH GARD), Cambridge University Press, and the Madrid Ministry of Education. Today's nfcol.net is independently maintained as an open, ad-free bilingual clinical reference and is not affiliated with the former 2010–2019 Bogota organization.

Following the expiration of the original domain after 2019, third-party domain squatters briefly parked unrelated template pages on the domain in 2021–2022. Upon restoring nfcol.net as a dedicated neurofibromatosis medical reference, our engineering and editorial team permanently isolated all non-medical squatter paths via HTTP 410 Gone directives while restoring 100% of the original 2010–2019 neurofibromatosis educational paths (/NF-1.html, /NF-2.html, /schwan.html, /tratamientos.html, /medicamentos.html, /examenes.html, /genetica.html, /mitos.html, and /vocabulario.html) to updated 2026 clinical chapters so readers arriving from NIH GARD and academic textbooks land directly on peer-reviewed guidance.

2. Clinical Evidence Standards & Independence

  • Primary Guideline Hierarchy: All diagnostic thresholds, nomenclature, and surveillance intervals are anchored strictly to peer-reviewed international consensus statements—specifically the International Consensus Group on Neurofibromatosis Diagnostic Criteria (Legius et al., 2021; Plotkin et al., 2022), American Academy of Pediatrics guidelines (Miller et al., 2019), ERN GENTURIS guidelines, and FDA/EMA regulatory trial datasets (SPRINT, KOMET, ReNeu).
  • Zero Commercial Conflict: nfcol.net accepts zero pharmaceutical funding, banner advertising, or sponsored drug placement. Comparisons between selumetinib (AstraZeneca/Alexion) and mirdametinib (SpringWorks Therapeutics) present trial endpoints and toxicity monitoring neutrally.
  • Medical Disclaimer: Content on nfcol.net is designed to support—never replace—direct evaluation by a board-certified medical geneticist, neurologist, neuro-ophthalmologist, or oncologist.

3. Editorial Corrections & Contact

Clinicians, patient advocates, medical librarians, and researchers wishing to report a guideline update or broken archival citation may reach our editorial desk directly at editorial@nfcol.net.

Frequently Asked Clinical Questions

Is nfcol.net sponsored by any pharmaceutical manufacturer?

No. nfcol.net is an independent, non-commercial medical reference with zero pharmaceutical sponsorship, advertising, or affiliate revenue.

Why do links from NIH GARD Spanish neurofibromatosis pages lead to nfcol.net?

US NIH GARD indexed nfcol.net across its Spanish pages for Neurofibromatosis, NF1, NF2, and Schwannomatosis during the site's original 2010–2019 tenure as Todo Sobre Neurofibromatosis. All historical Spanish URLs are preserved and updated to 2026 consensus standards.

Key Consensus Guidelines & Primary Sources

  1. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021;23(8):1506–1513. PubMed 34012067.
  2. Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genetics in Medicine. 2022;24(9):1967–1977. PubMed 35674741.
  3. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas (SPRINT Phase II). New England Journal of Medicine. 2020;382(15):1430–1442. PubMed 32187457.
  4. Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: A pivotal phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. Journal of Clinical Oncology. 2025;43(7):758–769. PubMed 39514828.
  5. Miller DT, Freedenberg D, Schorry E, et al. Health supervision for children with neurofibromatosis type 1 (American Academy of Pediatrics). Pediatrics. 2019;143(5):e20190660. PubMed 30988031.